Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.
Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…
Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The tiny German biotech needs strong signals to emerge from an approaching read out of its chemokine-targeting lead project.
A partnering deal with J&J worth $300m in upfront cash, over a largely ignored second pipeline candidate, should put the Belgian biotech firmly on the map.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.